Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression

Pharmacological Reports

Volumn 62, Issue 2, 2010, Pages 245-257

  Devadoss, Thangaraj ^a   Pandey, Dilip K ^a   Mahesh, Radhakrishnan ^a   Yadav, Shushil K ^b  

^a Pharmacy Group   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3; Antagonist; Antidepressant like effect; Forced swim test; Olfactory bulbectomy

Indexed keywords

(4 BENZYLPIPERAZIN 1 YL) (QUINOXALIN 2 YL)METHANONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 HYDROXYTRYPTOPHAN; AMFEBUTAMONE; FLUOXETINE; PARGYLINE; PAROXETINE; PARTHENOLIDE; QCF 3; RESERPINE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG; (4-BENZYLPIPERAZIN-1-YL)(QUINOXALIN-2-YL)METHANONE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; FORCED SWIMMING TEST; HEAD TWITCH; HYPOTHERMIA; LOCOMOTION; MALE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PSYCHOPHARMACOLOGY; RAT; RODENT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MOTOR ACTIVITY; MOUSE; OLFACTORY BULB; PHYSIOLOGY; WISTAR RAT;

5-HYDROXYTRYPTOPHAN; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; MICE; MOTOR ACTIVITY; OLFACTORY BULB; PIPERAZINES; QUINOXALINES; RATS; RATS, WISTAR; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS;

EID: 77953312242     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70263-2     Document Type: Article

References (66)

1. Blandina P, Goldfarb J, Walcott J, Green JP: Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther, 1991, 256, 341-347.
2. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ: Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry, 1997, 58, 137-145.
3. Boissier JR, Simon P: Action of caffeine on the spontaneous motility of the mouse. Arch Int Pharmacodyn Ther, 1965, 158, 212-221.
4. Borsini F, Meli A: Is the forced swimming test a suitable model for revealing anti-depressant activity? Psychopharmacology, 1988, 94, 147-160.
5. Bourin M, Fiocco AJ, Clenet F: How valuable are animal models in defining anti-depressant activity? Hum Psychopharmacol Clin, 2001, 16, 9-21.
6. Bourin M: Is it possible to predict the activity of a new anti-depressant in animals with simple psychopharmacological tests? Fund Clin Pharmacol, 1990, 4, 49-64.
7. Brady JV, Nauta WJ: Subcortical mechanisms in emotional behavior: the duration of affective changes following septal and habenular lesions in the albino rat. J Comp Physiol Psychol, 1955, 48, 412-420.
8. Costall B, Naylor RJ: 5-HT3 Receptors. Curr Drug Targets CNS Neurol Disord, 2004, 3, 27-37.
9. Cryan JF, Valentino RJ, Lucki I: Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev, 2005, 9, 547-569.
10. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry, 1992, 149, 443-454.
11. Deakin JF: Depression and 5-HT. Int Clin Pyschopharmacol, 1991, 6, 23-28.
12. Englert LF, Ho BT, Taylor D: The effects of (-)-_9-tetrahydrocannabinol on reserpine-induced hypothermia in rats. Br J Pharmacol, 1973, 49, 243-252.
13. Filip M, Bader M: Overview of 5-HT receptor and their role in physiology and pathology of of the central nervous system. Pharmacol Rep, 2009, 61, 761-777.
14. Fukuchi T, Kanemoto K: Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case control study. Int Clin Psychopharmacol, 2000, 17, 53-58.
15. Greenshaw AJ: Behavioral pharmacology of 5-HT, receptor antagonists: A critical uptake on therapeutic potential. Trends Pharmacol Sci, 1992, 14, 265-270.
16. Harms AE: An efficient synthesis of 2-quinoxalinecarboxylic Acid. Org Proc Res Dev, 2004, 8, 666-669.
17. Hibert MF, Hoffmann R, Miller RC, Carr AA: Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J Med Chem, 1990, 33, 1594-1600.
18. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Edincott J et al.: The national depressive and manic-depressive association consensus statement on the undertreatment of depression. JAMA, 1997, 277, 333-340.
19. Holsboer F: Therapeutics for depression and anxiety disorders. Drug Discov Today Ther Strateg, 2004, 1, 105-109.
20. Israili ZH: Clinical pharmacology of serotonin receptor type 3 (5-HT3) antagonists. Curr Med Chem - CNS Agents, 2001, 1, 171-199.
21. Jantunen IT, Kataja VV, Muhonen TT: An overview of randomized studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer, 1997, 33, 66-74.
22. Katona CLE, Hunter BN, Bray J: A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry, 1998, 13, 100-108.
23. Kelly JP, Wyrnn AS, Leonard BE: Olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997, 74, 299-316.
24. Kessler RC, McGonagle KA, Zhao A: Lifetime and 12- month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry, 1994, 51, 8-19.
25. Kilpatrick GJ, Butler A, Ireland SJ, Michel AD, Tyers MB: Affinities of 5-HT uptake inhibitors for 5-HT, receptors in both binding and functional studies. Br J Pharmacol, 1989, 98, Suppl, 859P.
26. Leonard M, Tuite M: Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol, 1981, 22, 251-286.
27. Lore R, Flannelly K, Farina P: Ultrasounds produced by rats accompany decrease in intra specific fighting. Aggress Behav, 1976, 2, 175-181.
28. Lucki I: The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol, 1997, 8, 523-532.
29. Lucki I, Singh A, Kreiss DS: Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev, 1997, 18, 85-95.
30. Lumia AR, Teicher MH, Salchli F, Ayers E, Possidente B: Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res, 1992, 587, 181-185.
31. Luscombe GP, Martin KF, Hutchins LJ, Gosden J, Heal DJ: Mediation of the anti-depressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Br J Pharmacol, 1993, 108, 669-677.
32. Mahesh R, Perumal RV, Pandi PV: Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie, 2005, 60, 83-96.
33. Mahesh R, Perumal RV, Pandi PV: Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8- naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorg Med Chem Lett, 2004, 14, 5179-5181
34. Mahesh R, Rajkumar R, Minasri B, Venkatesha Perumal R: Potential antidepressants: pharmacology of 2-(4- methylpiperazin-1-yl)-1,8-naphthyridine-3 carbonitrile in rodent behavioral models. Pharmazie, 2007, 60, 919-924.
35. Marles RJ, Kaminski J, Arnason JT, Pazos-Sanou L, Heptinstall S, Fischer NH, Crompton C et al.: A bioassay for inhibition of serotonin release from bovine platelets. J Nat Prod, 1992, 55, 1044-1056.
36. Martin P, Massol J, Soubrie P, Puech AJ: Effects of triiodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head twitches in mice. Prog Neuropsychopharmacol Biol Psychiatry, 1989, 13, 735-748.
37. Massie MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monographs, 2004, 32, 57-71.
38. McWilliams LA, Cox BJ, Enns MW: Mood and anxiety disorders associated with chronic pain and examination in a nationally representative sample. Pain, 2003, 106, 127-133.
39. Nestler EJ, Michel B, Ralph J, DiLeone AJ, Eisch SJ: Neurobiology of depression. Neuron, 2002, 34, 13-25.
40. O'Neill MF, Conway MW: Role of 5-HT1A and 5-HT1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology, 2001, 24, 391-398.
41. Ortmann R, Martin S, Radeke E, Delini Stula A: Interaction of beta-adrenoreceptor agonists with the serotonergic system in rat brain. A behavioural study using the L-5-HTP syndrome. Naunyn Schmiedeberg's Arch Pharmacol, 1981, 316, 225-230.
42. Páez-Pereda M: New drug targets in the signalling pathways activated by antidepressants. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29, 1010-1016.
43. Pandey DK, Ramamoorthy R, Mahesh R, Radha R: Depressant-like effects of parthenolide in rodent behavioural antidepressant test battery. J Pharm Pharmacol, 2008, 60, 1643-1650.
44. Peters JA, Malone HM, Lambert JJ: Recent advances in the electrophysiological characterization of 5-HT, receptors. Trends Pharmacol Sci, 1992, 13, 391-397.
45. Pirl WF: Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monographs, 2004, 32, 32-39.
46. Porsolt RD, Bertin A, Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977, 229, 327-336.
47. Rajkumar R, Pandey DK, Mahesh R, Radha R: 1-(m- Chlorophenyl) piperazine induces depressogenic-like behaviour in rodents by inhibiting the neuronal 5 HT2A receptors: proposal of a modified rodent anti-depressant assay. Eur J Pharmacol, 2009, 608, 32-41.
48. Ramamoorthy R, Radhakrishnan M, Borah M: Antidepressant- like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol, 2008, 19, 29-40.
49. Randrup A, Munkvad I, Fog R, Gerlach J, Molander L, Kjellberg B, Scheel-Kruger J: Mania, depression and brain dopamine. In: Current developments in psychopharmacology. Eds. Essman, WB, Valzelli L, Spectrum Publications, New York, 1975, 206-248.
50. Redrobe JP, Bourin M: Partial role of 5-HT3, and 5-HT2, receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol, 1997, 325, 129-135.
51. Rueter LE, Fornal CA, Jacobs BL: A critical review of 5-HT brain microdialysis and behavior. Rev Neurosci, 1997, 8, 117-137.
52. Schafer WR: How do antidepressant work? Prospect for genetic analysis of drug mechanism. Cell, 1999, 98, 551-554.
53. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ: (1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane)- induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther, 1995, 273, 101-112.
54. Shibata S, Nakanishi H, Watanabe S, Ueki S: Effects of chronic administration of antidepressants on mousekilling behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav, 1984, 21, 225-230.
55. Shibata S, Watanabe S: Facilitatory effect of olfactory bulbectomy on 2-deoxyglucose uptake in rat amygdale slices. Brain Res, 1994, 665, 147-150.
56. Slotkin TA, Miller DB, Fumagali F, Mccook EC, Zhang J, Bissette G, Seidler FJ: Modeling geriatric depression in animals: biochemical and behavioural effects of olfactory bulbectomy in young versus aged rats. J Pharmacol Exp Ther, 1999, 289, 334-345.
57. Song C, Leonard BE: The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev, 2005, 29, 627-647.
58. Stahl SM, Grady M: Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry, 2003, 64, 13-17.
59. Steru L, Chermat R, Thierry B Simon P: The tail suspension test: a new method for screening antidepressants. Psychopharmacology, 1985, 85, 367-370.
60. Thomas DA, Takahashi LK, Barfield RJ: Analysis of ultrasonic vocalizations emitted by residents during aggressive encounters among rats (Rattus norvegicus). J Comp Psychol, 1983, 97, 201-206.
61. Thomson AJ, Lummis SC: The 5-HT3 receptor as a therapeutic target. Expert Opin Therap Targets, 2007, 11, 527-540.
62. Van Reizen H, Leonard BE: Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory bulbectomised rats. Pharmacol Ther, 1990, 47, 21-34.
63. Van Riezen H, Leonard BE: Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. In: Psychopharmacology of Anxiolytics and Antidepressants, Ed. File SE, Pergamon Press, New York, 1991, 231-250.
64. Vivian JA, Miczek KA: Opioid suppression of distress ultrasounds after social defeat in rats. Neurosci Abst, 1990, 16, 443-447.
65. Wolf H: Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol, 2000, 29, 37-45.
66. Zifa E, Fillion G: 5-Hydroxytryptamine receptors. Pharmacol Rev, 1992, 44, 401-458.